Your browser is no longer supported. Please, upgrade your browser.
NexImmune, Inc.
Index- P/E- EPS (ttm)- Insider Own10.90% Shs Outstand22.58M Perf Week0.09%
Market Cap270.74M Forward P/E- EPS next Y-2.81 Insider Trans9.59% Shs Float14.13M Perf Month-34.56%
Income- PEG- EPS next Q-0.51 Inst Own43.10% Short Float2.33% Perf Quarter-44.69%
Sales- P/S- EPS this Y-42.80% Inst Trans0.03% Short Ratio11.30 Perf Half Y-
Book/sh9.54 P/B1.12 EPS next Y-9.80% ROA- Target Price- Perf Year-
Cash/sh4.66 P/C2.29 EPS next 5Y- ROE- 52W Range10.12 - 28.00 Perf YTD-57.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.86% Beta-
Dividend %- Quick Ratio20.20 Sales past 5Y- Gross Margin- 52W Low5.53% ATR0.95
Employees44 Current Ratio20.20 Sales Q/Q- Oper. Margin- RSI (14)30.64 Volatility6.52% 8.20%
OptionableNo Debt/Eq0.00 EPS Q/Q12.40% Profit Margin- Rel Volume0.23 Prev Close10.92
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume29.09K Price10.68
Recom2.00 SMA20-16.49% SMA50-31.94% SMA200-41.97% Volume6,721 Change-2.20%
Apr-01-21Initiated Raymond James Outperform $30
Mar-09-21Initiated Cantor Fitzgerald Overweight $35
Mar-09-21Initiated Barclays Overweight $35
Jul-27-21 04:01PM  
Jul-14-21 04:01PM  
Jun-16-21 04:29PM  
May-27-21 08:00AM  
May-19-21 04:21PM  
May-17-21 04:01PM  
May-12-21 04:51AM  
Apr-21-21 07:30AM  
Apr-13-21 12:04PM  
Mar-31-21 04:54PM  
Mar-02-21 04:01PM  
Feb-24-21 08:30AM  
Feb-23-21 08:00AM  
Feb-17-21 06:34PM  
Feb-11-21 10:03PM  
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trainer JohnChief Financial OfficerJul 08Option Exercise5.173,43217,74361,770Jul 09 04:19 PM
Trainer JohnChief Financial OfficerJun 08Option Exercise5.173,43217,74358,338Jun 09 04:06 PM
Trainer JohnChief Financial OfficerMay 08Option Exercise5.173,43217,74354,906May 19 04:16 PM
Trainer JohnChief Financial OfficerApr 08Option Exercise5.173,43217,74351,474May 19 04:16 PM
Trainer JohnChief Financial OfficerMar 10Option Exercise5.173,43217,74348,042Mar 12 02:00 PM
Jones KristiChief Operating OfficerFeb 17Buy17.0091115,48763,078Feb 19 04:30 PM
ZELDIS JEROME BExecutive VP of Research & DevFeb 17Buy17.005,88299,9945,882Feb 19 04:30 PM
Verstandig GrantDirectorFeb 17Buy17.00175,0002,975,000714,895Feb 19 04:25 PM
BARER SOL JDirectorFeb 17Buy17.0060,0001,020,0001,538,013Feb 19 04:20 PM